Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guided TherapeuticsGTHP 22 EV-to-OCF is -22.99 as of Aug. 11, 2026. GuruFocus rates GTHP with a GF Score™ of 22/100. The stock has 4 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Guided Therapeutics ranks better than 88.39% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Guided Therapeutics's Enterprise Value is $31.13 Mil.
Guided Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.35 Mil. Therefore, Guided Therapeutics's EV-to-OCF for today is -22.99.
The historical rank and industry rank for Guided Therapeutics's EV-to-OCF or its related term are showing as below:
GTHP'
s EV-to-OCF Range Over the Past 10 Years
Min: -46.98 Med: -10.32 Max: -3.1
Current: -22.99
During the past 13 years, the highest EV-to-OCF of Guided Therapeutics was -3.10. The lowest was -46.98. And the median was -10.32.
GTHP's EV-to-OCF is ranked better than 88.39% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.85
vs GTHP: -22.99
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Guided Therapeutics's PE Ratio (TTM) for today is calculated as:
Guided Therapeutics's share price for today is $0.29.
Guided Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Guided Therapeutics EV-to-OCF Related Terms
Guided Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Guided Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Guided Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guided Therapeutics EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Guided Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Guided Therapeutics's EV-to-OCF falls into.
Guided Therapeutics's current Enterprise Value is $31.13 Mil.
Guided Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guided Therapeutics (GTHP) has a EV-to-OCF of -22.99 as of Aug. 11, 2026. According to the industry distribution chart, Guided Therapeutics ranks #99 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 11.6%.
Is Guided Therapeutics' EV-to-OCF too high?
Guided Therapeutics' current EV-to-OCF is -22.99. Based on the distribution chart, Guided Therapeutics ranks #99 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Guided Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Guided Therapeutics' EV-to-OCF compare to PETV and FOFA?
According to the Medical Devices & Instruments industry distribution chart, Guided Therapeutics ranks #99 out of 853 companies for EV-to-OCF. This places Guided Therapeutics in the top 12% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 7.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.85, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guided Therapeutics's current EV-to-OCF is -22.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guided Therapeutics stock overvalued right now?
Guided Therapeutics (GTHP) has a current EV-to-OCF of -22.99. The current EV-to-OCF is -22.99. Guided Therapeutics' overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Guided Therapeutics (GTHP), the current EV-to-OCF is -22.99 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and the extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.
22GF Score
Get the complete analysis for GTHP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GTHP has been successfully added to your 
